1. The new pattern for dual NOTCH pathway involving nuclear transcription and mitochondrial regulation supports therapeutic mechanism of 4-butyl benzophenone derivatives against SIRS.
- Author
-
Song, Jiayu, Peng, Dan, Peng, Yu, Zhao, Guang, Ren, Yuan, Guo, Lina, Ren, Luyao, Zhang, Xiaohui, Xie, Xiaoxia, Zhang, Yajie, Cao, Lingya, and Li, Yunlan
- Subjects
- *
SYSTEMIC inflammatory response syndrome , *GENETIC transcription regulation , *STRUCTURE-activity relationships , *LIVER proteins , *LEAD compounds , *UBIQUITINATION , *BENZOPHENONES - Abstract
The systemic inflammatory response syndrome (SIRS) represents a self-amplifying cascade of inflammatory reactions and pathophysiological states triggered by infectious or non-infectious factors. The identification of disease targets and differential proteins in the liver (the unique and important immune organ) of SIRS mice treated with the lead compound D1 was conducted using the Genecards database and proteomic analysis, respectively. Subsequently, NOTCH1 was identified as the potential hub target via an intersection analysis between the aforementioned differentially expressed proteins and disease targets. Based on our previous research on the structure-activity relationship, we designed and synthesized a series of SIRS-related derivatives, wherein butyl, halogen, and ester groups were incorporated into benzophenone, aiming at exploring the anti-inflammatory protective action from the perspective of macrophage polarization. Notably, these derivatives exhibited a direct binding capability to the O-glucosylation site (SER496) or its vicinities (such as SER492, VAL485) of NOTCH1 using docking, SPR, DARTS, and CETSA techniques. Mechanistically, derivative D6 exerted anti-inflammatory effects via the dual NOTCH pathway. Firstly, it could inhibit NOTCH1 nuclear transcriptional activity, attenuate the interaction between NICD and RBPJK, concurrently suppress NF-κB and NLRP3 inflammasome (NLRP3, ASC, and cleaved CASP1) activation, and promote NICD (NOTCH1 active fragments) ubiquitination metabolism (the nuclear transcriptional pathway). Secondly, it might possess the ability to increase PGC1α level, subsequently, enhance ATP and MMP levels, mitigate ROS production, increase mitochondrial numbers, and ameliorate mitochondrial inflammatory damage (the mitochondrial pathway). Importantly, the activator Jagged1 could effectively reverse the aforementioned effects, while the inhibitor DAPT exhibited a synergistic effect, suggesting that the nuclear transcriptional regulation and mitochondrial regulation were both in a NOTCH1-dependent manner. Subsequently, it effectively alleviated the inflammatory response and preserved organ function as evidenced by up-regulating M2-type macrophage-related anti-inflammatory cytokines (IL10, TGFβ, CD206, and ARG1) and down-regulating M1-type macrophage-related pro-inflammatory cytokines (NO, IL6, IL18, iNOS, TNFα, CD86, and IL1β). In a word, derivative D6 modulated macrophage polarization and effectively mitigated SIRS by targeting inhibition of the dual NOTCH pathway. [Display omitted] In this study, we designed and synthesized a series of benzophenone derivatives targeting NOTCH1, which exhibited anti-inflammatory properties. Notably, the representative derivative D6 demonstrated the ability to promote M2 macrophage polarization while inhibiting M1 polarization, thereby restoring the delicate balance between M1 and M2 immune responses in the treatment of systemic inflammatory response syndrome (SIRS). This effect was primarily attributed to its targeted inhibition of the NOTCH1 signaling pathway at both the transcriptional and mitochondrial levels. Importantly, this discovery unveiled a novel single-target dual-regulatory model involving nuclear transcriptional regulation (NOTCH1/NF-κB/NLRP3/ubiquitination pathway) as well as mitochondrial regulation (NOTCH1/PGC1α pathway). These findings will offer valuable insights for clinical prevention and treatment strategies for SIRS while providing a theoretical foundation for the development of 4-butylbenzophenone derivatives. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF